信迪利单抗联合索拉非尼治疗晚期原发性肝癌的效果

摘要/Abstract

摘要： 目的观察信迪利单抗联合索拉非尼治疗晚期原发性肝癌(primary liver carcinoma,PLC)的效果及安全性。方法采用前瞻性的研究方法,应用随机数字表法将2019年7月至2022年1月无锡904医院收治的晚期PLC患者198例分为试验组与对照组。比较两组持续治疗3个周期的抗肿瘤疗效、肿瘤标志物、免疫功能、肝功能、药物安全性及1年内的生存情况。结果试验组抗肿瘤疗效[客观缓解率(41.41% vs. 26.26％),临床控制率(76.77% vs. 60.61%)]优于对照组(P<0.05),安全性(31.31% vs. 28.28%)及生存情况差异无统计学意义(P>0.05)。治疗后,试验组癌胚抗原[(15.24±3.01)ng/mL]、甲胎蛋白[(119.84±20.19)ng/mL]、糖类抗原199[(98.32±16.38)U/mL]、Th1/Th2[(4.98±0.64)]、Th17/Treg[(1.03±0.16)]、CD4⁺/CD8⁺[(1.41±0.21)]水平均优于对照组[(19.87±3.25)ng/mL、(152.31±28.69)ng/mL、(128.65±20.34)U/mL、(5.39±0.72)、(1.21±0.18)、(1.23±0.19)](P<0.05)。结论信迪利单抗与索拉非尼的联合治疗可有效降低晚期PLC患者的肿瘤标志物水平,改善患者免疫功能,且安全性高。

关键词: 信迪利单抗, 索拉非尼, 晚期原发性肝癌, 效果, 安全性

Abstract: Objective To observe the efficacy and safety of sintilimab combined with sorafenib in the treatment of advanced primary liver carcinoma (PLC). Methods Using the prospective study method, 198 patients with advanced PLC admitted to Wuxi 904 Hospital from July 2019 to January 2022 were divided into the experimental group and control group. The anti-tumor efficacy, tumor markers, immune function, liver function, drug safety and survival within 1 year of continuous treatment were compared between the two groups after 3 cycles of continuous treatment. Results The anti-tumor efficacy [objective remission rate (41.41% vs. 26.26) and clinical control rate (76.77% vs. 60.61%)] of the test group was better than that of the control group (P<0.05), and there was no difference in safety (31.31% vs. 28.28%) and survival (P>0.05). After treatment, carcinoembryonic antigen [(15.24±3.01) ng/mL], alpha-fetoprotein [(119.84±20.19) ng/mL], glycan antigen 199 [(98.32±16.38) U/mL], Th1/Th2 [(4.98±0.64)], and Th17/Treg [(1.03±0.16)], and CD4⁺/CD8⁺ [(1.41±0.21)] levels in the study group were better than those in the control group [(19.87±3.25) ng/mL, (152.31±28.69) ng/mL, (128.65±20.34) U/mL, (5.39±0.72), (1.21±0.18), (1.23±0.19)] (P< 0.05). Conclusion The combination of sintilimab and sorafenib can effectively reduce the level of tumor markers in patients with advanced PLC, improve the immune function of patients, and have a high safety profile.

Key words: Sindilimab, Sorafenib, Advanced primary liver cancer, Effect, Security

周晓秋, 孔丽霞, 许艳. 信迪利单抗联合索拉非尼治疗晚期原发性肝癌的效果[J]. 肝脏, 2026, 31(2): 220-223.

ZHOU Xiao-qiu, KONG Li-xia, XU Yan. Effect of sindilizumab combined with sorafenib in the treatment of advanced primary liver cancer[J]. Chinese Hepatolgy, 2026, 31(2): 220-223.

/ 推荐

参考文献

[1] 张国坤,张天佑,张景畅,等. 原发性肝癌患者TACE预后不良的因素分析:基于PSM法[J]. 国际医药卫生导报,2024,30(5):747-753.
[2] Liu F, Liao Z, Zhang Z. MYC in liver cancer: mechanisms and targeted therapy opportunities[J]. Oncogene, 2023, 42(45):3303-3318.
[3] Ganesan P, Kulik L M. Hepatocellular Carcinoma: new Developments[J]. Clin Liver Dis, 2023, 27(1):85-102.
[4] Yau T, Park J W, Finn R S, et al. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial[J]. Lancet Oncol, 2022, 23(1):77-90.
[5] Kong F H, Ye Q F, Miao X Y, et al. Current status of sorafenib nanoparticle delivery systems in the treatment of hepatocellular carcinoma[J]. Theranostics, 2021, 11(11):5464-5490.
[6] Llovet J M, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2022, 19(3):151-172.
[7] Donne R, Lujambio A. The liver cancer immune microenvironment: Therapeutic implications for hepatocellular carcinoma[J]. Hepatology, 2023, 77(5):1773-1796.
[8] 国家卫生健康委办公厅. 原发性肝癌诊疗指南(2022年版)[J]. 中华外科杂志,2022,60(4):273-309.
[9] Dueck A C, Mendoza T R, Mitchell S A, et al. Validity and reliability of the US national cancer institute′s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE)[J]. JAMA Oncol, 2015, 1(8):1051-1059.
[10] 周林荣,姚清深,陈宁,等. 甲磺酸阿帕替尼对晚期原发性肝癌患者临床缓解率及不良反应的影响[J]. 现代诊断与治疗,2019,30(18):3161-3162.
[11] 王楚风,蒋安. 原发性肝癌的分子诊断[J]. 中华肝脏外科手术学电子杂志,2023,12(5):499-503.
[12] 张永红,储建华,陈国栋. Callispheres-TACE术联合信迪利单抗治疗不可切除肝细胞癌的有效性[J]. 肝脏,2024,29(2):202-207.
[13] 王俊洁,徐龙,袁国盛,等. 信迪利单抗联合仑伐替尼二线治疗不可切除肝细胞肝癌的临床疗效及安全性[J]. 实用医学杂志,2022,38(9):1130-1135.
[14] 滕颖,丁晓燕,李文东,等. 程序性细胞死亡受体1抑制剂联合仑伐替尼治疗晚期原发性肝癌的效果及不良反应[J]. 临床肝胆病杂志,2021,37(3):606-610.
[15] 卢芳,施尧,张晨曦,等. 信迪利单抗治疗晚期肝癌的有效性及安全性分析[J]. 医学研究与战创伤救治,2023,36(8):852-855.
[16] 惠锋,马守成,裴霞霞. 信迪利单抗、贝伐珠单抗联合肝动脉化疗栓塞术在中晚期肝癌患者中的临床应用[J]. 中国现代医学杂志,2024,34(6):86-91.
[17] 覃雪,丁莉,蒋蜀梅. 肝动脉灌注化疗栓塞术联合信迪利单抗治疗晚期原发性肝癌近期疗效及远期生存率[J]. 安徽医药,2024,28(2):390-395.
[18] Lu S, Wu L, Jian H, et al. Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial[J]. Lancet Oncol, 2022, 23(9):1167-1179.
[19] 梁雄,伍楚蓉,唐武兵,等. 介入治疗联合仑伐替尼及信迪利单抗治疗中晚期肝癌的近期疗效观察[J]. 现代肿瘤医学,2023,31(20):3812-3817.
[20] Ren Z, Xu J, Bai Y, et al. Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study[J]. Lancet Oncol, 2021, 22(7):977-990.